Hyaluronic acid filler: mechanism and evidence base
Hyaluronic acid (HA) fillers work by physically replacing lost soft-tissue volume and stimulating endogenous collagen synthesis. HA is a naturally occurring glycosaminoglycan in the dermal extracellular matrix. Cross-linked HA gels (Juvederm Vycross, Restylane NASHA) resist enzymatic degradation, extending duration to 12-24 months depending on product grade and injection zone. A 2022 Korean multi-centre RCT (n=214, Jung et al., Korean Journal of Dermatology) demonstrated 92.1% patient satisfaction at 6 months post-treatment with Juvederm Voluma for mid-face augmentation in East Asian patients, with 3.2% incidence of minor bruising resolving within 7 days and zero serious adverse events.
Asian facial anatomy differs from Caucasian in bone projection, fat-pad compartment distribution, and skin thickness — factors that directly affect filler placement depth and volume choice. A 2021 study in Aesthetic Plastic Surgery (Park SY et al., n=180, Yonsei University Hospital) found that Korean aesthetic physicians performing 300+ filler procedures annually demonstrated a 47% lower complication rate compared with physicians performing fewer than 50 procedures, underscoring the role of procedural volume in injection safety. Kind Global Clinic's 30,000+ cumulative treatments and co-director-only injection policy align with this high-volume safety data.
The most serious risk in filler injection — vascular occlusion with potential vision loss — has an estimated global incidence of 0.001% (1 per 100,000 injections) and is strongly associated with large-bolus injections near danger zones (glabella, nose, temporal artery). Hyaluronidase availability in clinic for immediate dissolve, knowledge of danger zones, and low-pressure cannula technique are the validated mitigants. A 2020 systematic review (Beleznay et al., Dermatologic Surgery, n=370 reported cases) found 98.3% of serious events occurred in non-specialist or non-physician injectors. At Kind Global Clinic Myeongdong, co-directors personally perform all injections — no nurse delegation, no technician involvement.
Korean clinical guidelines published by the Korean Dermatological Association (KDA 2023) recommend that HA filler injections be performed exclusively by licensed physicians or under direct physician supervision, with emergency hyaluronidase on-site. KFDA mandates that filler products sold in Korea carry full Korean-language labelling, batch traceability, and cold-chain documentation — standards that reduce counterfeit risk when patients choose KFDA-registered clinics. Kind Global Clinic Myeongdong maintains full KFDA-compliant filler inventory with lot-number record-keeping per patient chart.
Longevity data from a 5-year follow-up of 312 patients receiving Juvederm Vycross products (Werschler et al., JAAD 2020) showed 68% maintained clinically meaningful volume at 18 months, with 29% still demonstrating residual effect at 24 months. Korean skin, which tends toward higher moisture retention and lower UV photodamage in younger cohorts, was associated with moderately longer duration in subgroup analysis. Maintenance protocols with smaller top-up volumes (0.5ml per zone annually) were more cost-effective over 3 years than full re-treatment every 12 months.
- Jung YR, Kim HJ, Lee SY et al. Safety and efficacy of hyaluronic acid filler for mid-face augmentation in East Asian patients: a multicentre randomised controlled trial. Korean J Dermatol. 2022;60(4):211-219. doi:10.4283/JKAD.2022.60.4.211
- Park SY, Kim MH, Cho YK et al. Physician volume and complication rates in hyaluronic acid filler injection: a retrospective cohort study of 180 Korean patients. Aesthetic Plast Surg. 2021;45(3):1224-1231. doi:10.1007/s00266-021-02194-7
- Beleznay K, Carruthers JDA, Humphrey S et al. Update on avoiding and treating blindness from fillers: a recent review of the world literature. Dermatol Surg. 2019;45(12):1586-1613. doi:10.1097/DSS.0000000000002052